Cohance to invest $10 million to expand cGMP bioconjugation capabilities in US
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
This strategic investment strengthens Cohance's integrated oligonucleotide platform
The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland
The company expects meaningful revenue contribution from this long-term agreement
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
Strengthening capabilities in Peptide Therapeutics and CDMO services
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
Subscribe To Our Newsletter & Stay Updated